Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time. 

Type
Public
HQ
Austin, US
Size (employees)
914 (est)+15%
Luminex is headquartered in Austin, US

Luminex Office Locations

Luminex has offices in Austin, Madison, 's-Hertogenbosch, Toronto and in 2 other locations
Austin, US (HQ)
12212 Technology Blvd
Shanghai, CN
Room 353 No.3058 Pusan Road
Minato Ku, JP
Kamiyacho Sankei Bldg 3 F 1 7 2 Azabudai
Toronto, CA
900 439 University Ave
's Hertogenbosch, NL
1 Het Zuiderkruis
Madison, US
1224 Deming Way

Luminex Data and Metrics

Luminex Financial Metrics

Luminex's revenue was reported to be $270.6 m in FY, 2016 which is a 14% increase from the previous period.
USD

Revenue (FY, 2016)

270.6 m

Revenue growth (FY, 2015 - FY, 2016), %

14%

Gross profit (FY, 2016)

179.7 m

Gross profit margin (FY, 2016), %

66%

Net income (FY, 2016)

13.8 m

EBIT (FY, 2016)

21 m

Market capitalization (21-Jul-2017)

902.8 m

Cash (31-Dec-2016)

93.5 m
Luminex's current market capitalization is $902.8 m.
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

10.7 m227 m237.7 m270.6 m

Revenue growth, %

2021%5%14%

Cost of goods sold

69.8 m67.1 m69 m91 m

Gross profit

(59.1 m)159.9 m168.7 m179.7 m

Gross profit Margin, %

(552%)70%71%66%

R&D expense

48.7 m

General and administrative expense

99.5 m

Operating expense total

138.9 m131.7 m131.4 m158.7 m

EBIT

4.8 m28.1 m37.4 m21 m

EBIT margin, %

45%12%16%8%

Pre tax profit

11.4 m28.1 m33 m19.6 m

Income tax expense

6.1 m9.5 m10.4 m(4.3 m)11 m3.8 m(5.8 m)

Net Income

7.1 m39 m36.9 m13.8 m
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

90.8 m89.5 m58.3 m42.8 m67.9 m91.7 m128.5 m93.5 m

Accounts Receivable

30.9 m29.1 m28.9 m32.4 m

Inventories

40.8 m

Current Assets

146.4 m177 m209.5 m173.7 m

PP&E

32.8 m39.9 m47.8 m57.4 m

Goodwill

50.7 m49.6 m49.6 m85.5 m

Total Assets

306 m357.5 m402.6 m450.7 m

Accounts Payable

10.7 m11.8 m7.9 m12.3 m

Total Debt

1.7 m1.7 m

Current Liabilities

28.5 m30.4 m27.2 m40.2 m

Total Liabilities

47 m

Additional Paid-in Capital

296.9 m309.4 m321.7 m336.4 m

Retained Earnings

(27.8 m)11.3 m48.1 m68.9 m

Total Equity

269.6 m320 m368.5 m403.7 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

7.1 m39 m36.9 m13.8 m

Depreciation and Amortization

15.9 m14.2 m

Accounts Receivable

2.3 m2 m

Accounts Payable

962 k841 k

Cash From Operating Activities

26.9 m49.3 m36.9 m

Purchases of PP&E

(18.1 m)(17.1 m)

Cash From Investing Activities

2.7 m(28.5 m)

Cash From Financing Activities

(4.4 m)3.4 m
Y, 2016

Financial Leverage

1.1 x

Luminex Operating Metrics

FY, 2015FY, 2016

Patents Pending

199166

Patents Issued

364563

Luminex Market Value History

Luminex Median Salaries

Source: 16 public H-1B filings from Luminex

Luminex Online and Social Media Presence

Luminex Company Life and Culture

You may also be interested in